Literature DB >> 24030100

Phosphatase of regenerating liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive prometastatic signal transduction.

Chad D Walls1, Anton Iliuk, Yunpeng Bai, Mu Wang, W Andy Tao, Zhong-Yin Zhang.   

Abstract

Phosphatase of regenerating liver 3 (PRL3) is suspected to be a causative factor toward cellular metastasis when in excess. To date, the molecular basis for PRL3 function remains an enigma, making efforts at distilling a concerted mechanism for PRL3-mediated metastatic dissemination very difficult. We previously discovered that PRL3 expressing cells exhibit a pronounced increase in protein tyrosine phosphorylation. Here we take an unbiased mass spectrometry-based approach toward identifying the phosphoproteins exhibiting enhanced levels of tyrosine phosphorylation with a goal to define the "PRL3-mediated signaling network." Phosphoproteomic data support intracellular activation of an extensive signaling network normally governed by extracellular ligand-activated transmembrane growth factor, cytokine, and integrin receptors in the PRL3 cells. Additionally, data implicate the Src tyrosine kinase as the major intracellular kinase responsible for "hijacking" this network and provide strong evidence that aberrant Src activation is a major consequence of PRL3 overexpression. Importantly, the data support a PDGF(α/β)-, Eph (A2/B3/B4)-, and Integrin (β1/β5)-receptor array as being the predominant network coordinator in the PRL3 cells, corroborating a PRL3-induced mesenchymal-state. Within this network, we find that tyrosine phosphorylation is increased on a multitude of signaling effectors responsible for Rho-family GTPase, PI3K-Akt, STAT, and ERK activation, linking observations made by the field as a whole under Src as a primary signal transducer. Our phosphoproteomic data paint the most comprehensive picture to date of how PRL3 drives prometastatic molecular events through Src activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24030100      PMCID: PMC3861722          DOI: 10.1074/mcp.M113.028886

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  106 in total

Review 1.  Protein tyrosine phosphatases: prospects for therapeutics.

Authors:  Z Y Zhang
Journal:  Curr Opin Chem Biol       Date:  2001-08       Impact factor: 8.822

Review 2.  The Nck family of adapter proteins: regulators of actin cytoskeleton.

Authors:  László Buday; Livius Wunderlich; Peter Tamás
Journal:  Cell Signal       Date:  2002-09       Impact factor: 4.315

Review 3.  Mechanisms and functions of Eph and ephrin signalling.

Authors:  Klas Kullander; Rüdiger Klein
Journal:  Nat Rev Mol Cell Biol       Date:  2002-07       Impact factor: 94.444

Review 4.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

Review 5.  PLC regulation: emerging pictures for molecular mechanisms.

Authors:  Tom D Bunney; Matilda Katan
Journal:  Trends Biochem Sci       Date:  2010-10-01       Impact factor: 13.807

6.  PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.

Authors:  Haihe Wang; Samantha Yiling Quah; Jing Ming Dong; Edward Manser; Jing Ping Tang; Qi Zeng
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

Review 7.  The Nck SH2/SH3 adaptor protein: a regulator of multiple intracellular signal transduction events.

Authors:  J H McCarty
Journal:  Bioessays       Date:  1998-11       Impact factor: 4.345

8.  Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts.

Authors:  J Su; M Muranjan; J Sap
Journal:  Curr Biol       Date:  1999-05-20       Impact factor: 10.834

9.  Interaction of the Nck adapter protein with p21-activated kinase (PAK1).

Authors:  G M Bokoch; Y Wang; B P Bohl; M A Sells; L A Quilliam; U G Knaus
Journal:  J Biol Chem       Date:  1996-10-18       Impact factor: 5.157

10.  PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.

Authors:  Lirong Peng; Xiaofang Xing; Weijun Li; Like Qu; Lin Meng; Shenyi Lian; Beihai Jiang; Jian Wu; Chengchao Shou
Journal:  Mol Cancer       Date:  2009-11-24       Impact factor: 27.401

View more
  14 in total

Review 1.  Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.

Authors:  Lakshmi Reddy Bollu; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

2.  A role of autophagy in PTP4A3-driven cancer progression.

Authors:  Yu-Han Huang; Abdul Qader O Al-Aidaroos; Hiu-Fung Yuen; Shu-Dong Zhang; Han-Ming Shen; Ewelina Rozycka; Cian M McCrudden; Vinay Tergaonkar; Abhishek Gupta; You Bin Lin; Jean Paul Thiery; James T Murray; Qi Zeng
Journal:  Autophagy       Date:  2014-08-01       Impact factor: 16.016

3.  PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Authors:  Min Thura; Abdul Qader Omer Al-Aidaroos; Wei Peng Yong; Koji Kono; Abhishek Gupta; You Bin Lin; Kousaku Mimura; Jean Paul Thiery; Boon Cher Goh; Patrick Tan; Ross Soo; Cheng William Hong; Lingzhi Wang; Suling Joyce Lin; Elya Chen; Sun Young Rha; Hyun Cheol Chung; Jie Li; Sayantani Nandi; Hiu Fung Yuen; Shu-Dong Zhang; Yeoh Khay Guan; Jimmy So; Qi Zeng
Journal:  JCI Insight       Date:  2016-06-16

Review 4.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

5.  Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.

Authors:  Adam C Searleman; Anton B Iliuk; Timothy S Collier; Lewis A Chodosh; W Andy Tao; Ron Bose
Journal:  Electrophoresis       Date:  2014-06-12       Impact factor: 3.535

6.  Expression array analysis of the hepatocyte growth factor invasive program.

Authors:  Fabiola Cecchi; Chih-Jian Lih; Young H Lee; William Walsh; Daniel C Rabe; Paul M Williams; Donald P Bottaro
Journal:  Clin Exp Metastasis       Date:  2015-08-01       Impact factor: 5.150

Review 7.  Protein tyrosine phosphatases as potential therapeutic targets.

Authors:  Rong-Jun He; Zhi-Hong Yu; Ruo-Yu Zhang; Zhong-Yin Zhang
Journal:  Acta Pharmacol Sin       Date:  2014-09-15       Impact factor: 6.150

8.  A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.

Authors:  Kelley E McQueeney; Joseph M Salamoun; Jennifer G Ahn; Paula Pekic; Isabella K Blanco; Heather L Struckman; Elizabeth R Sharlow; Peter Wipf; John S Lazo
Journal:  FASEB J       Date:  2018-05-10       Impact factor: 5.191

Review 9.  Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Authors:  Mariana Tannús Ruckert; Pamela Viani de Andrade; Verena Silva Santos; Vanessa Silva Silveira
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.207

10.  PRL-3 activates mTORC1 in Cancer Progression.

Authors:  Zu Ye; Abdul Qader Omer Al-Aidaroos; Jung Eun Park; Hiu Fung Yuen; Shu Dong Zhang; Abhishek Gupta; Youbin Lin; Han-Ming Shen; Qi Zeng
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.